Loading...
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy. Durable remissions are seen in 30% t...
Na minha lista:
| Udgivet i: | Blood |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6107879/ https://ncbi.nlm.nih.gov/pubmed/29914976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-04-839217 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|